Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin dose comparison in non-diabetic heart failure
IRCT20210828052313N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of empagliflozin in heart failure (HF) (3 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: major adverse cardiovascular event, medication side effects and 19 more. Started Nov 2021; status: completed.
02
Drugs
empagliflozin
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on IRCT20210828052313N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210828052313N1.